DanielWynnMDFACNS. FAASM
Neurology • Northbrook, ILEpilepsy, Headache, Neuroimmunology/Multiple Sclerosis, Sleep Medicine
Director, Clinical Research Director, Consultants in Neurology MS Center
Dr. Wynn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1535 Lake Cook Rd.
Suite 601
Northbrook, IL 60062Phone+1 847-509-0270Fax+1 847-509-0273
Summary
- Dr. Daniel Wynn is a board certified neurologist in Northbrook, IL and is affiliated with multiple hospitals in the area, including NorthShore Skokie Hospital, AMITA Health Saint Francis Hospital Evanston, Highland Park Hospital, Evanston Hospital, Glenbrook Hospital, Advocate Illinois Masonic Medical Center, Cancer Treatment Centers of America Chicago, and AMITA Health Resurrection Medical Center - Chicago.. He received his medical degree from Chicago Medical School at Rosalind Franklin University and has been in practice 34 years. He also speaks multiple languages, including Spanish. He specializes in multiple sclerosis, epilepsy, headache, and sleep medicine and is experienced in board certified in Neurology, Clinical NeurophysiiologyNeurophysiology (Epilepsy/Neuromuscular Disease/sleep medicine).
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Neurology, 1983 - 1987
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1983
Certifications & Licensure
IL State Medical License 1988 - 2026
MN State Medical License 1984 - 1989- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Clinical Neurophysiology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Most Compassionate Doctor American Registry
Clinical Trials
- Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis Start of enrollment: 2005 Apr 01
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
Publications & Presentations
PubMed
- 1 citationsTwenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.Mark S Freedman, Patricia K Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn
Neurology and Therapy. 2024-04-01 - Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis.Enrique Alvarez, Lawrence Steinman, Edward J Fox, Hans-Peter Hartung, Peiqing Qian
Frontiers in Neurology. 2024-01-01 - 3 citationsEffectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.Regina Berkovich, Donald Negroski, Daniel Wynn, Daniel Sellers, Kristen G Bzdek
Multiple Sclerosis and Related Disorders. 2023-02-01
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
